Browse the evidence

Magnitude of residual variation in weight was associated with all-cause mortality (relative risk, 1.25 for 1 U of additional variation; 95% CI, 1.06-1.47).

Practitioners should consider the impact of weight fluctuations on overall mortality risk.

Magnitude of residual variation in weight was associated with ischemic heart disease mortality (relative risk, 2.49; 95% CI, 1.41-4.38).

Weight management strategies should be carefully considered to reduce heart disease risk.

Weight loss interventions, if deemed to be necessary, should be considered carefully.

Practitioners should approach weight loss interventions with caution, considering potential risks.

Restraint, disinhibition, and physical activity level did not predict weight change.

Practitioners should note that traditional factors like restraint and activity may not be reliable indicators of weight change in this population.

The estimated health care cost offsets from clinical benefits of GLP-1RAs are projected to be $18.2 billion over 10 years.

Practitioners should consider the potential health care savings from clinical benefits of GLP-1RAs.

No significant effect of frequency was found for muscle hypertrophy.

Older adults may not experience additional muscle growth benefits from increasing resistance training frequency beyond two sessions per week.

No significant gender by time interaction was observed during the second 8-week phase of the resistance training program.

Results suggest that initial gender differences in training load may not persist over longer training periods.

There was no difference in mean total body weight change between IBD and non-IBD cohorts after semaglutide initiation.

Weight loss outcomes with semaglutide appear consistent regardless of IBD status.

Common complications associated with GLP-1 RA treatment include nausea, constipation, abdominal pain, and vomiting.

Healthcare providers should monitor patients for these common side effects when prescribing GLP-1 RA.

Recommendations have been made for the timely detection of micro- and macrovascular complications of diabetes.

Healthcare providers should prioritize monitoring for complications in diabetic patients.

85% of adolescents report no physical activity.

Strategies are needed to promote physical activity among adolescents.

GLP-1RAs have gastrointestinal side effects, particularly nausea, which limits their tolerability.

Clinicians should monitor for gastrointestinal side effects when prescribing GLP-1RAs.

Within the diabetes support and education (DSE) group, cardiovascular disease outcomes did not differ.

DSE alone may not be sufficient to impact cardiovascular outcomes compared to intensive lifestyle interventions.

Disparities in the use of SGLT-2 inhibitors and GLP-1 receptor agonists exist based on race, sex, and socioeconomic status.

Efforts should be made to address these disparities in prescribing practices.

The American and European guidelines have similar approaches to CVD prevention but also have some differences.

Clinicians should be aware of both similarities and differences in guidelines for tailored patient care.

Systolic blood pressure was not statistically different between traditional resistance training (RT) and high velocity resistance training (HVRT) at the beginning and during 30 minutes after sessions.

Both training modalities may be equally effective in managing systolic blood pressure in this population.

Traditional recommendations for obesity treatment are largely ineffective.

Practitioners should be aware that traditional methods may not yield results.

23% of participants reported any adverse event while using GLP-1RAs, with 7% discontinuing treatment.

While GLP-1RAs are generally well-tolerated, practitioners should monitor for adverse events.

HMB demonstrated no significant effect on body mass (BM) in athletes.

Athletes should not expect HMB to significantly affect their body weight.

HMB has a small, nonsignificant effect on fat mass (FM) in athletes.

HMB may have a minimal effect on reducing fat mass, but it is not statistically significant.

Higher BMI in monozygotic twins is associated with an increased risk of incident diabetes.

Practitioners should be aware that higher BMI in twins correlates with a higher risk of diabetes.

Increases in BMI over the past 30 years were not associated with later risk of myocardial infarction or death but were associated with the risk of incident diabetes.

Practitioners should note that long-term increases in BMI may not affect cardiovascular risk but do relate to diabetes risk.

Seven foods contributed 50% of total energy intake in the Mexican population aged 5 years and older.

Practitioners should focus on these key foods when addressing energy intake in dietary recommendations.

There is great heterogeneity in energy intake among different subgroups of the Mexican population.

Dietary interventions may need to be tailored to specific subgroups to be effective.